Press Release: European Medicines Agency recommends approval of fourth advanced therapy in Europe

Author (Corporate)
Series Title
Series Details EMA/394057/2013 (28.06.13)
Publication Date 28/06/2013
Content Type

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in June 2013, recommended granting a marketing authorisation for a new advanced-therapy medicinal product (ATMP). Provenge is recommended for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.
Source Link http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001835.jsp&mid=WC0b01ac058004d5c1
Related Links
EMA: Press Release: EMA/394057/2013 (28.06.13) http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/human/002513/WC500144937.pdf
Subject Categories
Countries / Regions